D-Trp6-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men

M. A. Rubio, I. Torres-Aleman, J. R. Calle, J. A. Cabranes, A. V. Schally, A. L. Charro

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The effect of a potent agonistic analog of LHRH, D-Trp6-LHRH, on hyperprolactinemia induced by sulpiride was studied in normal men. Six men received sulpiride (100 mg, twice daily, orally) for 44 days. D-Trp6-LHRH was given sc during the last 2 weeks of sulpiride administration; the dose was 500 ng on the first day and 100 μg daily for the subsequent 14 days. All men had high serum PRL levels before D-Trp6-LHRH administration (mean ± SEM, 56 ± 9 ng/mL), which decreased significantly after the first dose of the analog (45 ± 5 ng/mL; P = 0.031) and also after 15 days of analog administration (41 ± 6 ng/mL; P = 0.016). These data demonstrate that administration of LHRH agonist can inhibit the hyperprolactinemic effect of sulpiride, suggesting a direct action of the analog on the pituitary gland to modulate PRL secretion.

Original languageEnglish (US)
Pages (from-to)368-369
Number of pages2
JournalJournal of Clinical Endocrinology and Metabolism
Issue number2
StatePublished - Aug 1987
Externally publishedYes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'D-Trp<sup>6</sup>-luteinizing hormone-releasing hormone inhibits sulpiride-induced hyperprolactinemia in normal men'. Together they form a unique fingerprint.

Cite this